These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 23074112)

  • 1. EGFR polymorphism as a predictor of clinical outcome in advanced lung cancer patients treated with EGFR-TKI.
    Jung M; Cho BC; Lee CH; Park HS; Kang YA; Kim SK; Chang J; Kim DJ; Rha SY; Kim JH; Lee JH
    Yonsei Med J; 2012 Nov; 53(6):1128-35. PubMed ID: 23074112
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CYP1A1*2A polymorphism as a predictor of clinical outcome in advanced lung cancer patients treated with EGFR-TKI and its combined effects with EGFR intron 1 (CA)n polymorphism.
    Nie Q; Yang XN; An SJ; Zhang XC; Yang JJ; Zhong WZ; Liao RQ; Chen ZH; Su J; Xie Z; Wu YL
    Eur J Cancer; 2011 Sep; 47(13):1962-70. PubMed ID: 21616658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polymorphisms in epidermal growth factor receptor (EGFR) and AKT1 as possible predictors of clinical outcome in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors.
    Zhang X; Fan J; Li Y; Lin S; Shu P; Ni J; Qin S; Zhang Z
    Tumour Biol; 2016 Jan; 37(1):1061-9. PubMed ID: 26269114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic polymorphism in the epidermal growth factor receptor gene predicts outcome in advanced non-small cell lung cancer patients treated with erlotinib.
    Winther-Larsen A; Nissen PH; Jakobsen KR; Demuth C; Sorensen BS; Meldgaard P
    Lung Cancer; 2015 Nov; 90(2):314-20. PubMed ID: 26386832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung cancer harboring TKI-sensitive EGFR mutations: an exploratory study.
    Lee JK; Shin JY; Kim S; Lee S; Park C; Kim JY; Koh Y; Keam B; Min HS; Kim TM; Jeon YK; Kim DW; Chung DH; Heo DS; Lee SH; Kim JI
    Ann Oncol; 2013 Aug; 24(8):2080-7. PubMed ID: 23559152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Shorter EGFR Dinucleotide Repeat Length Predicts Better Response of Patients with Advanced Non-small Cell Lung Cancer to EGFR Tyrosine Kinase Inhibitor.
    Chen B; Luo J; Gu W; Shen L; Wang H; Zhou S
    Cell Biochem Biophys; 2015 Dec; 73(3):799-804. PubMed ID: 27259328
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical observation of EGFR-TKI as a first-line therapy on advanced non-small cell lung cancer].
    Li J; Qu L; Wei X; Gao H; Wang W; Qin H; Tang C; Guo W; Wang H; Liu X
    Zhongguo Fei Ai Za Zhi; 2012 May; 15(5):299-304. PubMed ID: 22613337
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidermal growth factor receptor polymorphisms and clinical outcomes in non-small-cell lung cancer patients treated with gefitinib.
    Liu G; Gurubhagavatula S; Zhou W; Wang Z; Yeap BY; Asomaning K; Su L; Heist R; Lynch TJ; Christiani DC
    Pharmacogenomics J; 2008 Apr; 8(2):129-38. PubMed ID: 17375033
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of single nucleotide polymorphisms on the efficacy and toxicity of EGFR tyrosine kinase inhibitors in advanced non-small cell lung cancer patients.
    Pérez-Ramírez C; Cañadas-Garre M; Molina MÁ; Cabeza Barrera J; Faus-Dáder MJ
    Mutat Res Rev Mutat Res; 2019; 781():63-70. PubMed ID: 31416579
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of BIM Deletion Polymorphism and BIM Expression as Predictive Biomarkers to Maximize the Benefit of EGFR-TKI Treatment in EGFR-Positive NSCLC.
    Incharoen P; Charonpongsuntorn C; Saowapa S; Sirachainan E; Dejthevaporn T; Kampreasart K; Trachu N; Muntham D; Reungwetwattana T
    Asian Pac J Cancer Prev; 2019 Dec; 20(12):3581-3589. PubMed ID: 31870097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Traditional Chinese Medicine Prolongs Progression-Free Survival and Enhances Therapeutic Effects in Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI)Treated Non-Small-Cell Lung Cancer (NSCLC) Patients Harboring EGFR Mutations.
    Tang M; Wang S; Zhao B; Wang W; Zhu Y; Hu L; Zhang X; Xiong S
    Med Sci Monit; 2019 Nov; 25():8430-8437. PubMed ID: 31704907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Observational Study of Treatment Patterns in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Non-Small Cell Lung Cancer After First-Line EGFR-Tyrosine Kinase Inhibitors.
    Nadler E; Pavilack M; Espirito JL; Clark J; Fernandes A
    Adv Ther; 2020 Feb; 37(2):946-954. PubMed ID: 31955357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of EGFR tyrosine kinase inhibitors in patients having EGFR-activating mutations with or without BIM polymorphisms.
    Ariyasu R; Yanagitani N; Tadokoro K; Yamaguchi T; Uchibori K; Kitazono S; Fujita N; Katayama R; Nishio M
    Cancer Chemother Pharmacol; 2020 Oct; 86(4):517-525. PubMed ID: 32948919
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation between efficacy of the EGFR tyrosine kinase inhibitor and serum tumor markers in lung adenocarcinoma patients.
    Pan JB; Hou YH; Zhang GJ
    Clin Lab; 2014; 60(9):1439-47. PubMed ID: 25291939
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monitoring of cyclooxygenase-2 levels can predict EGFR mutations and the efficacy of EGFR-TKI in patients with lung adenocarcinoma.
    Li H; Wang Y; Su F; Li J; Gong P
    Int J Clin Exp Pathol; 2015; 8(5):5577-83. PubMed ID: 26191267
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidermal growth factor receptor intron-1 polymorphism predicts gefitinib outcome in advanced non-small cell lung cancer.
    Tiseo M; Capelletti M; De Palma G; Franciosi V; Cavazzoni A; Mozzoni P; Alfieri RR; Goldoni M; Galetti M; Bortesi B; Bozzetti C; Loprevite M; Boni L; Camisa R; Rindi G; Petronini PG; Ardizzoni A
    J Thorac Oncol; 2008 Oct; 3(10):1104-11. PubMed ID: 18827605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the efficacies of first-generation epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in patients with advanced non-small-cell lung cancer harboring EGFR mutations.
    Aiko N; Shimokawa T; Miyazaki K; Misumi Y; Agemi Y; Ishii M; Nakamura Y; Yamanaka T; Okamoto H
    BMC Cancer; 2018 Oct; 18(1):1012. PubMed ID: 30348116
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The concomitant gene alterations impact the therapeutic efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors in advanced non-small cell lung cancer patients with epidermal growth factor receptor sensitive mutation].
    Li JM; Hu J; Bai CX; Zhang Y; Xu XB; Wang XD; Ding N
    Zhonghua Jie He He Hu Xi Za Zhi; 2018 Oct; 41(10):778-782. PubMed ID: 30347549
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21.
    Yu JY; Yu SF; Wang SH; Bai H; Zhao J; An TT; Duan JC; Wang J
    Chin J Cancer; 2016 Mar; 35():30. PubMed ID: 27001083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of genetic alterations associated with primary resistance to EGFR-TKIs in advanced non-small-cell lung cancer patients with EGFR sensitive mutations.
    Wang F; Diao XY; Zhang X; Shao Q; Feng YF; An X; Wang HY
    Cancer Commun (Lond); 2019 Mar; 39(1):7. PubMed ID: 30823937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.